Insider Purchases: Inside the Buy
Tag: High Risk High Reward
Insider Buys Shares of Mainz Biomed: Promising Science, Precarious Finances
Mainz Biomed’s cancer-screening science is compelling — and an insider just bought big. But with heavy losses, dilution risk, and a going-concern warning, MYNZ is a biotech moonshot best approached with extreme caution.
Insiders Buy Airship AI; Should You Invest Or Just Do Surveillance?
Insiders are buying Airship AI — but this micro-cap surveillance play comes with heavy risks, short pressure, and execution hurdles. Speculative by design. 🕵️♂️
Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?
NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.
Bakkt Holdings CEO Buys Shares; Are Profits Baked In?
Bakkt (BKKT) is back on the radar. With a new CEO buying $1.47M of stock and losses shrinking fast, is this crypto play baked to perfection—or half-baked hype?
Eastman Kodak (KODK): Insider Buys, Debt Drama & a Pivot to Pills?!
Eastman Kodak insiders are snapping up shares, with CEO Jim Continenza leading the charge. But Kodak’s finances are shaky, its debt heavy, and its pivot to pharmaceuticals uncertain. High risk, high reward — or just a faded picture?
Centene (CNC): CEO Buys at $25, Earnings Bleed Red, and the Stock’s on Life Support — Bargain or Bust?
Centene (CNC) just got a shot in the arm from its CEO and a director buying nearly $740K worth of stock near decade lows. But with Q2 earnings bleeding red, rising Medicaid costs, and valuation sliced in half, is this a bargain-bin opportunity or just a patient in the ICU?